Menu
← Oncology Approval Tracker
FDA DECISION ·
Prevymis oral pellets
letermovir · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Oral pellets to prevent cytomegalovirus infection and disease in seropositive allogeneic hematopoietic stem cell transplant recipients aged 6 months and older and weighing at least 6 kg. The formulation also has a separate kidney transplant indication.
LAMPGEN ANALYSIS
Why it matters
The pellet presentation adds an administration option when a transplant recipient cannot swallow a tablet.
What research teams should watch
Train caregivers on packet preparation and document formulation and weight at discharge to avoid a mismatch in home dosing.
PRIMARY RECORDS